TD Asset Management Inc Purchases 16,000 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

TD Asset Management Inc grew its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREFree Report) by 7.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 221,360 shares of the biopharmaceutical company’s stock after purchasing an additional 16,000 shares during the period. TD Asset Management Inc owned approximately 0.27% of Ultragenyx Pharmaceutical worth $10,585,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Ultragenyx Pharmaceutical by 3.1% in the third quarter. Vanguard Group Inc. now owns 7,233,168 shares of the biopharmaceutical company’s stock valued at $257,862,000 after acquiring an additional 214,666 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Ultragenyx Pharmaceutical by 0.4% in the third quarter. Wellington Management Group LLP now owns 5,195,880 shares of the biopharmaceutical company’s stock valued at $185,233,000 after acquiring an additional 18,359 shares during the last quarter. Federated Hermes Inc. increased its position in shares of Ultragenyx Pharmaceutical by 11.4% in the fourth quarter. Federated Hermes Inc. now owns 2,446,500 shares of the biopharmaceutical company’s stock valued at $116,992,000 after acquiring an additional 250,000 shares during the last quarter. Clearbridge Investments LLC increased its position in shares of Ultragenyx Pharmaceutical by 3.9% in the fourth quarter. Clearbridge Investments LLC now owns 2,383,492 shares of the biopharmaceutical company’s stock valued at $113,979,000 after acquiring an additional 89,922 shares during the last quarter. Finally, Rock Springs Capital Management LP increased its position in shares of Ultragenyx Pharmaceutical by 6.7% in the third quarter. Rock Springs Capital Management LP now owns 1,476,441 shares of the biopharmaceutical company’s stock valued at $52,635,000 after acquiring an additional 92,172 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

RARE has been the topic of a number of recent research reports. Canaccord Genuity Group lifted their target price on Ultragenyx Pharmaceutical from $109.00 to $111.00 and gave the company a “buy” rating in a research report on Friday. Royal Bank of Canada began coverage on Ultragenyx Pharmaceutical in a research report on Monday, April 22nd. They set an “outperform” rating and a $77.00 price target on the stock. Wedbush boosted their price target on Ultragenyx Pharmaceutical from $47.00 to $48.00 and gave the stock a “neutral” rating in a research report on Friday. Cantor Fitzgerald boosted their price target on Ultragenyx Pharmaceutical from $107.00 to $115.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Stifel Nicolaus boosted their price target on Ultragenyx Pharmaceutical from $124.00 to $127.00 and gave the stock a “buy” rating in a research report on Friday. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.67.

Get Our Latest Stock Report on RARE

Insider Transactions at Ultragenyx Pharmaceutical

In other news, Director Matthew K. Fust sold 12,195 shares of the company’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $50.88, for a total transaction of $620,481.60. Following the completion of the transaction, the director now directly owns 14,860 shares in the company, valued at $756,076.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP Thomas Richard Kassberg sold 11,509 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $49.93, for a total value of $574,644.37. Following the completion of the sale, the executive vice president now directly owns 252,823 shares in the company, valued at $12,623,452.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Matthew K. Fust sold 12,195 shares of the stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $50.88, for a total value of $620,481.60. Following the completion of the sale, the director now owns 14,860 shares of the company’s stock, valued at $756,076.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,846 shares of company stock worth $1,201,388. Corporate insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Trading Up 2.5 %

Shares of NASDAQ:RARE opened at $41.13 on Tuesday. The company has a fifty day moving average of $43.66 and a 200-day moving average of $45.02. Ultragenyx Pharmaceutical Inc. has a 52-week low of $31.52 and a 52-week high of $54.98.

Ultragenyx Pharmaceutical (NASDAQ:RAREGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.72) by ($0.31). The company had revenue of $108.83 million for the quarter, compared to analyst estimates of $116.03 million. Ultragenyx Pharmaceutical had a negative return on equity of 425.63% and a negative net margin of 138.58%. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the company posted ($2.33) earnings per share. As a group, equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.49 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Profile

(Free Report)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Featured Articles

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREFree Report).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.